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Abstract
Introduction: Assessment of systemic inflammatory response forms the basis of several scoring systems that attempt 
to prognosticate patients with periampullary pancreatic carcinoma (PPC). We assessed the validity of three of these 
scoring systems for patients’ prognosis following intervention for PPC: Glasgow prognostic score (GPS) and its 
modified version (mGPS), platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR).
Methods: EMBASE and MEDLINE databases were searched for all published studies until September 2018 using 
comprehensive text word and MeSH terms. Meta-analysis of observational studies in epidemiology guidelines was 
followed. All identified studies were analysed and relevant studies were included in the review.
Results: Three studies which assessed the role of GPS, four studies that evaluated the use of NLR and three that 
assessed the role of PLR in patients with PPC were identified. None of these studies demonstrated any value in the 
pre-operative assessment of patients with PPC. The limited number of studies available precluded further statistical 
analysis.
Conclusions: Based on available evidence, GPS, NLR and PLR do not appear to be useful scoring systems to predict 
prognosis of patients with PPC. Larger studies are warranted before the application of inflammatory scoring systems 
could be recommended in patients with PPC.
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Introduction
Periampullary pancreatic cancer (PPC) has an overall 5-year 
survival varying from 36 to 51%, with a median survival of 
66 months in patients who undergo resection.[1-3] Surgical 
resection is the only curative treatment for such cancers; 
however, resection is only possible in 15–20% of patients.[3] 
The mainstay of surgical resection is in the form of either 
pylorus-preserving pancreaticoduodenectomy (PPPD) or 
Kausch-Whipple’s procedure. Both PPPD and Kausch-
Whipple’s procedure have a reported perioperative 
morbidity of approximately 40%[4] and a reported mortality 
of 3% in high volume specialised centres.[5]
Improved patient selection, better imaging techniques and 
the introduction of adjuvant chemotherapy have improved 
patients’ outcomes in recent years. However, tumour 
behaviour remains difficult to assess preoperatively with 
only detailed post-operative histological examination 
allowing meaningful prognostic factors, such as lymph 
node status, histological subtype, tumour stage and margin 
status, to be fully defined.
There is thus a need for robust markers or biomarkers that 
could be used in the prognostic stratification of patients 
with PPC before surgical resection.
Scoring systems based on the assessment of the systemic 
inflammatory response have been shown to be useful pre-
intervention indicators of prognosis in various neoplastic 
conditions.[6-8] Commonly used scoring systems are the 
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Glasgow prognostic score (GPS), including its modified 
version (mGPS), the platelet-lymphocyte ratio (PLR) and 
the neutrophil-lymphocyte ratio (NLR). However, none 
of them have been adopted routinely into clinical practice 
and few have been externally validated. The role of these 
scoring systems in patients with PPC remains unexplored.
The aim of this review was to evaluate the evidence for 
the prognostic value of these scoring systems in predicting 
outcomes in patients with PPC, specifically assessing the 
ability to predict patient survival.
 Materials and Methods
A literature search was performed to identify all studies 
that examined the prognostic value of one or more of 
the three scoring systems in patients with PPC. All 
studies published from 1966 to 1st week September 2018 
were evaluated. EMBASE and MEDLINE databases 
were searched using comprehensive text and MeSH 
terms. Keywords used for search are listed as under 
(periampullary cancer*, periampullary carcinoma*, 
periampullary tumours*, periampullary adenocarcinoma*, 
GPS*, modified GPS*, GPS* or mGPS*, PLR*, PLR*, 
NLR* and NLR*). Google Scholar was used to identify 
additional manuscripts. A bibliography of included 
articles was hand searched for relevant additions. Two 
investigators independently searched and analysed all 
data, and consensus was sought with a third author where 
discrepancies existed.
Since all studies were observational, our search protocol 
was based on meta-analysis of observational studies in 
epidemiology guidelines.[9] All papers indexed in the 
English language were included. Case reports or case 
series, unpublished abstracts, proceedings of meetings 
and animal studies were excluded. After removal of 
duplicates and irrelevant articles, abstracts were screened 
for further exclusions. Full-text articles were then read 
before inclusion in the analysis. Assessment of bias 
in the studies was made using the risk of bias in non-
randomised studies of interventions (ROBINS-I) tool 
by two reviewers independently. The ROBINS-I tool 
assesses bias across six domains including confounding, 
participant selection, intervention classification, departure 
from intended interventions, missing data, measurement 
of outcomes and selection of reported results. For each 
domain, an outcome of low, moderate, serious, critical and 
no information for risk of bias is recorded. An overall risk 
of bias judgement is then determined through combination 
of the six domains.
The primary aim of our review was to assess if any of 
these scoring systems could be used to predict patient 
outcome in PPC.
Results
The results from searching the EMBASE and MEDLINE 
databases are presented in Table 1. Among the included 
studies, one focused on the prognostic value of GPS, 
Table 1: Search strategy (no filters) and results from 
searching EMBASE and MEDLINE databases











GPS* or mGPS* 22350 30622








6 or 7 or 8 1352 2276
PLR* 427 1713
PLR* 2000 3090
10 or 11 2083 3505
NLR* 1424 5552
NLR* 7122 7265
13 or 14 7553 9033
5 or 9 or 12 or 15 31982 43026
1 and 16 3 8
1 and 5 0 5
1 and 9 1 3
1 and 12 1 2
1 and 15 1 2
γ: Ovid MEDLINE® from 1966 to September 2018; φ EMBASE 
from 1974 to September 2018, GPS: Glasgow prognostic score, 
PLR: Platelet‑lymphocyte ratio, NLR: Neutrophil‑lymphocyte ratio
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two assessed NLR and three investigated the value of 
PLR in PC.
Three studies evaluated GPS in patients with PPC 
periods.[10,11] Garcea et al. described 137 patients with 
potentially resectable PPC lesions detected on pre-
operative imaging who were assessed for resectability 
at laparoscopy. Five patients had PPC in this series. 
Patient outcome after surgical intervention was not 
reported. GPS was assessed to see if it could be used 
to discriminate operability before laparoscopy, but 
no statistical difference was found.[10] Lowe et al. 
assessed that 302 patients had pancreatic resection for 
periampullary cancers, of which 45 had histologically 
confirmed PPC and 96% had an R0 resection. The data 
presented in this study did not allow for calculation of 
the GPS, and hence, this could not be assessed in the 
presented review. Kumamoto et al. assessed 84 patients 
and found that the GPS did not accurately predict post-
operative major complications.[12]
Four studies evaluated NLR in patients with 
PPC.[10,12-14] Garcea et al. demonstrated that NLR has no 
pre-operative value in discriminating between operable 
and non-operable disease and has no value in detecting 
occult disease.[10] Kumamoto et al. found that a higher 
NLR as associated with major complications.[12] Hamed 
et al. evaluated the use of NLR in 74 patients with 
periampullary tumours; they demonstrated that the 
median survival between patients having NLR >5 and 
<5 was not significantly different; however, in patients 
developing recurrence, NLR <5 was associated with 
improved survival.[13] Demirci et al. found that an NLR 
of more than 3 was associated with overall survival and 
disease-free survival.[14]
Three studies aimed to assess the role of PLR in patients 
with PC.[10,15-17] Garcea et al. showed no role of PLR 
in assessing the benefit of staging laparoscopy in PPC 
patients. Smith et al. included 263 pancreatic resections 
in their study, of which 48 had PPC. The authors 
demonstrated that pre-operative median PLR pf < or=150 
was significantly associated with locally advanced and 
metastatic disease in patients with periampullary lesions 
(P < 0.001), but this group included pancreatic ductal 
adenocarcinoma, cholangiocarcinoma and metastatic 
adenocarcinoma. Overall patient survival was not 
presented in this study although median PLR was 
specifically associated with increased risk of nodal disease 
in patients with PC (P = 0.002). Demirci et al. assessed 
82 patients with PPC and found that a PLR >212 was 
associated with a significantly worse overall survival.[17]
The limited data and heterogeneity of the studies were 
such that a meta-analysis was not possible and only a 
descriptive analysis of the studies was made.
Discussion
Patient outcome following surgical intervention for 
PPC depends on both tumour biology and patient-
related factors. The systemic inflammatory response is 
acknowledged to be an important factor in many tumours 
including PPC.[18] The mechanism of PPC development 
remains incompletely understood and is likely to involve 
chronic inflammation, immune cell activation and growth-
promoting signalling pathways.[19] The inflammatory 
response may serve as a potential parameter to help 
prognosis stratification with the aim to improve patient’s 
outcome.
In this review, we assessed elements of the inflammatory 
response evaluating the GPS, NLR and PLR scoring 
systems to investigate whether they can be helpful tools 
in patients’ stratification and, in particular, if they could 
predict resectability.[7,20] These scoring systems may 
allow pre-operative identification of aggressive tumours, 
thus changing the treatment strategy (e.g., neoadjuvant 
treatments) and provide individualised care. If reliable, 
they could also serve as useful monitoring tools after 
successful resection.
Many cancers have been shown to incite a systemic 
inflammatory response as evidenced by an elevated 
C-reactive protein (CRP). Indeed, a recent study by 
Shirai et al. has shown that in patients with pancreatic 
ductal cancer that demonstrates a significant inflammatory 
response have a poorer prognosis and poorer survival.[21] 
The fine mechanisms of these events remain elusive, 
but the release of pro-inflammatory cytokines such as 
tumour necrosis factor α and interleukin-6, modulation 
of endothelial cell function and angiogenesis seems to 
play a significant role.[22]
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GPS provides an objective scoring system that combines 
CRP and serum albumin.[23] There are reports of adverse 
outcomes in patients with hepatobiliary malignancy 
and elevated GPS.[24] Only one study was found which 
investigated the potential role of GPS in PPC, and 
unfortunately, this only assessed whether the scoring 
system could discriminate between patients with operable 
and non-operable disease. Therefore, it remains to be 
established if GPS or mGPS can be used as a pre-operative 
scoring system.
NLR is calculated from the differential count by 
dividing the absolute neutrophil count with the absolute 
lymphocyte count. NLR >5 is considered significant 
and a poor prognostic marker.[25] However, no study has 
clearly assessed the role NLR in predicting patient survival 
following a diagnosis of PPC. Although one study in 
our review did suggest that patients with NLR >5 were 
associated with inferior patient outcome in periampullary 
tumours when PPC was assessed, NLR was found not to 
be predictive.[13] It remains to be established if NLR could 
represent a useful tool in the pre-operative work-up in 
patients with PPC.
PLR is calculated in a similar manner as NLR but with 
the substitution of platelets for neutrophil count. There 
is some degree of discrepancy in defining a significant 
PLR; however, most studies stratified patients into 
three groups with a PLR <150, PLR 150–300 and PLR 
>300 indicating good, moderate and poor prognosis, 
respectively.[26] In our review, we found that two studies 
were from the same unit and covered the same study 
period. Hence, these data need to be interpreted carefully. 


























































































































































































































































































































































































































































































































































































Garcea et al. 137 5 GPS, NLR, PLR
Lowe et al. 302 45 Nil
Hamed et al. 228 61 NLR
Sakka et al. 34 3 PLR
Smith et al. 263 204 PLR
PPC: Periampullary pancreatic carcinoma, GPS: Glasgow prognostic 
score, NLR: Neutrophil‑lymphocyte ratio, PLR: Platelet‑lymphocyte 
ratio
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conclusion as to the utility of PLR in patients with PPC. 
It is possible that PLR may be associated with poorer 
patient outcome, but it was not statistically significant.
It is important to note that the quality of the studies 
available for this meta-analysis was of low quality 
[Table 2] with many studies being retrospective and 
in some cases with low numbers of patient with PPC 
[Table 3].
Conclusion
There is a lack of evidence within literature regarding 
the prognostic use of inflammatory scoring systems in 
PPC. In addition, the available studies are of low quality 
with heterogeneous patient cohorts, low numbers and are 
retrospective in nature. Further research and larger studies 
are needed before recommending these scoring systems 
in patients with PPC.
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